UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.474

Sortiert nach

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

British journal of dermatology (1951), 2012-09, Vol.167 (3), p.668-677

2012

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1395-1406

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

British journal of dermatology (1951), 2013-11, Vol.169 (5), p.992-999

2013

Link zum Volltext

Verfügbarkeit prüfen

托法替布在慢性斑块型银屑病中的获益风险特征

British journal of dermatology (1951), 2019-01, Vol.180 (1), p.e32-e32

2019

Link zum Volltext

Verfügbarkeit prüfen

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

British journal of dermatology (1951), 2019-01, Vol.180 (1), p.67-75

2019

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

Clinical pharmacology and therapeutics, 2017-12, Vol.102 (6), p.1006-1016

2017

Link zum Volltext

Verfügbarkeit prüfen

Association between serum interleukin‐17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis

Clinical and experimental dermatology, 2018-10, Vol.43 (7), p.790-797

2018

Link zum Volltext

Verfügbarkeit prüfen

Obesity-related cardiovascular disease: implications of obstructive sleep apnea

Diabetes, obesity & metabolism, 2006-05, Vol.8 (3), p.250-260

2006

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib benefit‐risk profile in chronic plaque psoriasis

British journal of dermatology (1951), 2019-01, Vol.180 (1), p.e19-e19

2019

Link zum Volltext

Verfügbarkeit prüfen

Association between plasma adiponectin levels and unstable coronary syndromes

European heart journal, 2007-02, Vol.28 (3), p.292-298

2007

Link zum Volltext

Verfügbarkeit prüfen

Arrhythmogenic mechanisms in left ventricular hypertrophy

Europace (London, England), 2000-07, Vol.2 (3), p.216-223

Wolk, R

2000

Link zum Volltext

Verfügbarkeit prüfen

THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.253-253

2016

Link zum Volltext

Verfügbarkeit prüfen

Leptin receptor and functional effects of leptin in human endothelial progenitor cells

Atherosclerosis, 2005-11, Vol.183 (1), p.131-139

2005

Link zum Volltext

Verfügbarkeit prüfen

Extrasystolic beats affect transmural electrical dispersion during programmed electrical stimulation

European journal of clinical investigation, 2001-04, Vol.31 (4), p.293-301

2001

Link zum Volltext

Verfügbarkeit prüfen

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

CPT: pharmacometrics and systems pharmacology, 2017-05, Vol.6 (5), p.322-330

2017

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.841-850

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects

Clinical pharmacology and therapeutics, 2009-10, Vol.86 (4), p.430-437

2009

Link zum Volltext

Verfügbarkeit prüfen

066 Incidence rates and prevalence of hospital-treated alopecia areata in Denmark (1995-2016)

Journal of investigative dermatology, 2022-12, Vol.142 (12), p.S191-S191

2022

Link zum Volltext

Verfügbarkeit prüfen

Pupillary Pain Index Changes After a Standardized Bolus of Alfentanil Under Sevoflurane Anesthesia: First Evaluation of a New Pupillometric Index to Assess the Level of Analgesia During General Anesthesia

Anesthesia and analgesia, 2019-03, Vol.128 (3), p.467-474

2019

Link zum Volltext

Verfügbarkeit prüfen

598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S102-S102

2023

Link zum Volltext

Verfügbarkeit prüfen

EPH57 Epidemiology of Alopecia Areata Across Global Regions – A Systematic Literature Review

Value in health, 2022-12, Vol.25 (12), p.S202-S202

2022

Link zum Volltext

Verfügbarkeit prüfen

Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

CPT: pharmacometrics and systems pharmacology, 2013-05, Vol.2 (5), p.1-8

2013

Link zum Volltext

Verfügbarkeit prüfen

Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy

Pharmacology & therapeutics (Oxford), 1999-11, Vol.84 (2), p.207-231

1999

Link zum Volltext

Verfügbarkeit prüfen

Obesity, Sleep Apnea, and Hypertension

Hypertension (Dallas, Tex. 1979), 2003-12, Vol.42 (6), p.1067-1074

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.474

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.307)
Mit Volltextzugriff
(1.327)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

托法替布在慢性斑块型银屑病中的获益风险特征

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

Association between serum interleukin‐17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis

Obesity-related cardiovascular disease: implications of obstructive sleep apnea

Tofacitinib benefit‐risk profile in chronic plaque psoriasis

Association between plasma adiponectin levels and unstable coronary syndromes

Arrhythmogenic mechanisms in left ventricular hypertrophy

THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials

Leptin receptor and functional effects of leptin in human endothelial progenitor cells

Extrasystolic beats affect transmural electrical dispersion during programmed electrical stimulation

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects

066 Incidence rates and prevalence of hospital-treated alopecia areata in Denmark (1995-2016)

Pupillary Pain Index Changes After a Standardized Bolus of Alfentanil Under Sevoflurane Anesthesia: First Evaluation of a New Pupillometric Index to Assess the Level of Analgesia During General Anesthesia

598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study

EPH57 Epidemiology of Alopecia Areata Across Global Regions – A Systematic Literature Review

Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy

Obesity, Sleep Apnea, and Hypertension

Suchergebnisse filtern